Pharmacokinetics of Dipyridamole Administered as Aggrenox® (Dipyridamole Extended Release Plus Aspirin) Capsule Versus Dipyridamole Immediate Release Plus Aspirin Following Alteration of Stomach pH

Inclusion Criteria: * Healthy subjects as determined by results of screening * Signed written informed consent in accordance with Good Clinical Practice (GCP) and local legislation * Age 40 - 65 years, inclusive, at time of Visit 1 * Stomach pH \> 4.0 on three consecutive measurements separated by at least five minutes, measured at Visits 3B and 5B prior to dosing with Aggrenox or dipyridamole-aspirin (DP-ASA) Exclusion Criteria: * Any findings of the medical examination (including blood pressure, pulse rate and ECG) deviating from normal and considered by the investigator to be of clinical relevance * Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders considered by the investigator to be of clinical relevance * History of gastro-intestinal ulcer, perforation or bleeding * Surgery of the gastro-intestinal tract (except appendectomy) * Diseases of the central nervous system (such as epilepsy), neurological disorders, or psychiatric disorders * Chronic or relevant acute infections. Screening tests will be performed for HIV, hepatitis B, and hepatitis C * History of hypersensitivity to Aggrenox or any of the components or excipients * Intake of drugs with a long dominant half-life (\>24 hours) 1 month or less prior to Visit 1 * Use of any drugs which might influence the results of the trial ten days or less prior to Visit 1 * Participation in another trial with an investigational drug 1 month or less prior to Visit 1 * Known alcohol abuse * Known drug abuse (a drug screening test will be performed at Visits 1, 3, and 5) * Blood donation 1 month or less prior to Visit 1 * Excessive physical activities five days or less prior to Visit 1 * History of hemorrhagic diathesis * History of bronchial asthma * Any laboratory value outside the reference range, considered by the investigator to be of clinical relevance For female subjects: * Nursing * Pregnancy * Positive pregnancy test * No adequate contraception (adequate contraception includes sterilization, intrauterine device, or oral contraceptives) * Inability to maintain adequate contraception during the whole study period